Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)’s share price gapped up prior to trading on Monday . The stock had previously closed at $7.41, but opened at $7.59. Marinus Pharmaceuticals shares last traded at $7.84, with a volume of 3011600 shares changing hands.

MRNS has been the topic of several analyst reports. ValuEngine raised Marinus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, July 25th. JMP Securities reissued an “outperform” rating and issued a $11.00 target price (up previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Tuesday, September 12th.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.02.

Institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp bought a new stake in shares of Marinus Pharmaceuticals in the third quarter worth about $128,000. Citadel Advisors LLC increased its holdings in shares of Marinus Pharmaceuticals by 327.8% in the third quarter. Citadel Advisors LLC now owns 51,383 shares of the biopharmaceutical company’s stock worth $301,000 after acquiring an additional 39,371 shares in the last quarter. KCG Holdings Inc. increased its holdings in shares of Marinus Pharmaceuticals by 29.5% in the first quarter. KCG Holdings Inc. now owns 64,539 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 14,692 shares in the last quarter. EAM Investors LLC bought a new stake in shares of Marinus Pharmaceuticals in the third quarter worth about $554,000. Finally, Jennison Associates LLC increased its holdings in shares of Marinus Pharmaceuticals by 108.1% in the second quarter. Jennison Associates LLC now owns 811,665 shares of the biopharmaceutical company’s stock worth $1,112,000 after acquiring an additional 421,600 shares in the last quarter. Institutional investors own 20.56% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Marinus Pharmaceuticals, Inc. (MRNS) Shares Gap Up to $7.59” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/11/13/marinus-pharmaceuticals-inc-mrns-shares-gap-up-to-7-59.html.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Receive News & Stock Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.